Crispr Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Oppenheimer issued their Q1 2020 earnings per share (EPS) estimates for Crispr Therapeutics in a report released on Tuesday, November 12th, according to Zacks Investment Research. Oppenheimer analyst S. Tuerkcan anticipates that the company will earn ($0.87) per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $80.00 target price on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ FY2021 earnings at ($4.29) EPS, FY2022 earnings at ($4.70) EPS and FY2023 earnings at ($1.07) EPS.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The firm had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million.

Several other research analysts have also issued reports on the stock. ValuEngine upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Chardan Capital restated a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a report on Monday, November 18th. William Blair upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a research note on Tuesday, November 19th. Finally, TheStreet upgraded shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $69.54.

Crispr Therapeutics stock opened at $71.65 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $74.00. The firm has a 50 day moving average price of $49.98 and a two-hundred day moving average price of $46.23. The firm has a market cap of $3.76 billion, a price-to-earnings ratio of -20.83 and a beta of 3.15.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BSW Wealth Partners acquired a new stake in Crispr Therapeutics in the 2nd quarter valued at $39,000. Balyasny Asset Management LLC purchased a new position in Crispr Therapeutics during the 2nd quarter worth $5,165,000. BNP Paribas Arbitrage SA purchased a new position in Crispr Therapeutics during the 2nd quarter worth $41,000. Bank of New York Mellon Corp boosted its holdings in Crispr Therapeutics by 116.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock worth $1,559,000 after acquiring an additional 17,810 shares during the last quarter. Finally, ARK Investment Management LLC boosted its holdings in Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after acquiring an additional 701,332 shares during the last quarter. 49.81% of the stock is owned by institutional investors and hedge funds.

In related news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock valued at $3,620,760 in the last quarter. 21.40% of the stock is currently owned by company insiders.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Read More: Profit Margin

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link